- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07841431
Neuromodulation for Functional Recovery After Stroke (VNS-EARLY)
This study used a multicenter, double-blind, randomized controlled design. The trial protocol was jointly designed by the principal investigator and an executive committee composed of experts in functional neurosurgery, cerebrovascular disease, and rehabilitation medicine. The study enrolled patients in the subacute phase (3-6 months) after ischemic stroke with upper limb motor impairment. All patients were implanted with a vagus nerve stimulation (VNS) device and randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group.
This study used the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity. The primary endpoint was the difference in FMA-UE score between the active VNS group and the control group at the end of 6 weeks of hospital treatment. Secondary endpoints included changes from baseline in FMA-UE score and WMFT score at 90 days, among others. This study evaluates the safety and efficacy of vagus nerve stimulation for improving upper limb motor function in patients in the subacute phase after stroke, ultimately providing clinical evidence for the diagnosis and treatment of this patient population.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This study uses a multicenter, double-blind, randomized controlled design. Eligible participants all undergo implantation of a VNS device and are randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group. The study hypothesizes that vagus nerve stimulation is effective in improving upper limb motor function in patients in the subacute phase after stroke; that is, a meaningful difference in FMA-UE scores exists between the active VNS group and the control group at the end of 6 weeks of hospital treatment. All enrolled participants undergo implantation of a vagus nerve stimulation device. After preoperative assessment, patients undergo implantation of the vagus nerve stimulation device under general anesthesia. After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). This trial uses the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity, with a pretreatment baseline assessment performed 1 week after implantation. Stimulation testing is performed in 0.1 mA increments in both groups to assess the level at which participants can perceive and tolerate stimulation. Hospital treatment begins on the day after baseline assessment.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Xuesong Bai, Dr.
- Telefonnummer: 86 18810032664
- E-Mail: bxsben@163.com
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- History of unilateral supratentorial ischemic stroke and in the subacute phase (3-6 months);
- Age between 18-80 years, both male and female;
- FMA-UE score of 20-50 (inclusive);
- Ability to communicate, understand, and provide appropriate consent; participant can follow two-step commands;
- Right or left upper limb weakness;
- Active flexion/extension of the wrist or fingers;
- Informed consent signed by the patient or a family member.
Exclusion Criteria:
- History of hemorrhagic stroke;
- Persistent dysphagia or choking/coughing while eating or drinking;
- Medications that, at study initiation, may significantly interfere with the effects of VNS on neurotransmitter systems;
- Prior vagus nerve injury, bilateral or unilateral (e.g., injury during carotid endarterectomy);
- Severe or more severe depression (Beck Depression Inventory >29);
- Candidates unsuitable for device implantation surgery (e.g., history of adverse reaction to anesthesia, deemed unsuitable as a surgical candidate by the surgeon, etc.);
- Current use of any other stimulation device, such as a pacemaker or other neurostimulator; current use of any other investigational device or drug;
- Preexisting neurological or psychiatric disorders before stroke onset that affect assessment of the condition;
- Pregnancy, planned pregnancy, or breastfeeding during the study period;
- Severe upper limb spasticity (modified Ashworth ≥3);
- Severe sensory loss. Sensory loss will be measured using the upper extremity sensory portion of the Fugl-Meyer Assessment. The assessment involves light touch (two items) and proprioception (four items). The maximum score is 12; subjects with a score below 6 will be excluded from the study;
- Other conditions that the investigator considers unsuitable for participation or that may pose a significant risk to the patient.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Active VNS group
After implantation, participants randomized to active VNS (0.8 mA) combined with upper limb rehabilitation. |
After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). To reduce the risk of participants inferring treatment assignment, participants in both treatment groups receive five stimuli of decreasing intensity at the beginning of each treatment session (starting at 0.8 mA and then decreasing by 0.1 mA at each step), after which treatment is administered according to randomization. |
|
Schein-Komparator: Control VNS group
After implantation, participants randomized to control VNS (0 mA) combined with upper limb rehabilitation. |
After implantation, participants randomized to Control VNS (0.8 mA) combined with upper limb rehabilitation. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The difference in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) scores between the active VNS group and the control group at the end of 6 weeks of hospital treatment.
Zeitfenster: At the end of 6 weeks of hospital treatment.
|
The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function. |
At the end of 6 weeks of hospital treatment.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Clinically meaningful improvement in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days (≥6-point improvement in FMA-UE score);
Zeitfenster: 90 days
|
The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function. |
90 days
|
|
Change from baseline in Wolf Motor Function Test (WMFT) score at 90 days
Zeitfenster: 90 days
|
The WMFT Functional Ability Scale ranges from 0 to 75, with higher scores indicating better upper-extremity function. |
90 days
|
|
Change from baseline in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days
Zeitfenster: 90 days
|
The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function. |
90 days
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from baseline in Stroke Impact Scale (SIS) score at 90 days
Zeitfenster: 90 days
|
The SIS score ranges from 0 to 100, with higher scores indicating better health status and functioning. |
90 days
|
|
Change from baseline in Stroke-Specific Quality of Life (SS-QOL) score at 90 days
Zeitfenster: 90 days
|
The SS-QOL total score ranges from 49 to 245, with higher scores indicating better quality of life. |
90 days
|
|
Change from baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index score at 90 days
Zeitfenster: 90 days
|
The EuroQol 5-Dimension 5-Level utility index ranges from -0.391 to 1.000, with higher scores indicating better health-related quality of life. |
90 days
|
|
Change from baseline in Motor Activity Log (MAL) score at 90 days
Zeitfenster: 90 days
|
Each MAL subscale ranges from 0 to 5, with higher scores indicating better real-world use and movement quality of the affected upper extremity. |
90 days
|
|
Change from baseline in Beck Depression Inventory (BDI) total score at 90 days
Zeitfenster: 90 days
|
The BDI total score ranges from 0 to 63, with higher scores indicating more severe depressive symptoms and therefore a worse outcome. |
90 days
|
|
Adverse events: adverse events occurring during the study period (including the surgical procedure);
Zeitfenster: From study enrollment through the Day 90 follow-up visit, including the perioperative period.
|
From study enrollment through the Day 90 follow-up visit, including the perioperative period.
|
|
|
Device complications: any unexpected adverse reactions of the device
Zeitfenster: From device implantation through the Day 90 follow-up visit.
|
From device implantation through the Day 90 follow-up visit.
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- 1. 王拥军, et al., 中国卒中报告2019(中文版)(1). 中国卒中杂志, 2020. 15(10): p. 1037-1043. 2. Nakayama, H., et al., Recovery of upper extremity function in stroke patients: The Copenhage n stroke study. Archives of Physical Medicine and Rehabilitation. 75(4): p. 394-398. 3. Opara, J.A. and K. Jaracz, Quality of life of post-stroke patients and their caregivers. J Med Life, 2010. 3(3): p. 216-20. 4. Butt, M.F., et al., The anatomical basis for transcutaneous auricular vagus nerve stimulation. J Anat, 2020. 236(4): p. 588-611. 5. van der Meij, A. and M.J.H. Wermer, Vagus nerve stimulation: a potential new treatment for ischaemic strok e. Lancet (London, England). 397(10284): p. 1520-1521. 6. Ay, I., et al., Transcutaneous Cervical Vagus Nerve Stimulation Ameliorates Acute Isch emic Injury in Rats. Brain stimulation. 9(2): p. 166-73. 7. Kimberley, T.J., et al., Vagus Nerve Stimulation Paired With Upper Limb Rehabilitation After Ch ronic Stroke. Stroke. 49(11): p. 2789-2792. 8. Dawson, J., et al., Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. Stroke, 2016. 47(1): p. 143-50. 9. Dawson, J., et al., Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet, 2021. 397(10284): p. 1545-1553. 10. Grefkes, C. and G.R. Fink, Recovery from stroke: current concepts and future perspectives. Neurological Research and Practice, 2020. 2(1): p. 17.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- VNS-EARLY
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The VNS-EARLY Steering Committee will consider on a case-by-case basis requests for data sharing.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .